ARTICLE | Product Development
Partners announce PFS benefit from monotherapy head-to-head. Summit’s Phase III program outside China adds chemotherapy to the mix
By Paul Bonanos, Director of Biopharma Intelligence
May 31, 2024 12:59 AM UTC
Akeso’s bispecific therapy ivonescimab has scored a victory in a China-only head-to-head study versus Keytruda in NSCLC, more than tripling shares of partner Summit about 18 months after the U.S. biotech paid $500 million for the molecule’s rights in major markets.
The trial pitted ivonescimab against Keytruda pembrolizumab monotherapy rather than in combination with chemotherapy, as it’s most often used, but Summit’s ongoing multiregional Phase III program is incorporating chemo…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652570/summit-reaps-benefit-of-akeso-deal-as-bispecific-beats-keytruda-head-to-head-in-china-only-nsclc-study